Supply Chains Are Orderly. Biotech Innovation Is Messy

Katrine Bosley, former CEO of Avila Therapeutics, states that drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Her preferred strategy would be two-way, iterative partnerships bringing together big drugmakers' experience with small biotechs' innovation.

Embedded Link

Supply Chains Are Orderly. Biotech Innovation Is Messy | Xconomy
I was intrigued by the concept of an “innovation supply chain” for biotech raised in last week’s Xconomy discussion with Noubar Afeyan of Flagship Ventures

Google+: View post on Google+

Published by

Cliff

Walking Enthusiast, Technology Transfer Advisor @ Concordia University, Intellectual Property Valuation Expert @ Kalotem & Amateur Photographer.